Table 1.
Studies comparing the hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients treated with entecavir vs. tenofovir.
| First Author | Year | Design | Race | Country | Mean Age (yr) | Males ETV n (%) |
Males TDF n (%) |
Total Patient n (%) |
ETV n (%) |
TDF n (%) |
HCC in ETV n (%) |
HCC in TDF n (%) |
Cirrhosis before ETV n (%) |
Cirrhosis before TDF n (%) |
HbeAg Pos ETV n (%) |
HbeAg Pos TDF n (%) |
HBV DNA Baseline ETV (Log IU/mL) |
HBV DNA Baseline TDF (Log IU/mL) |
BMI ETV | BMI TDF | DM ETV n (%) |
DM TDF n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Riveiro-Barciela [52] | 2017 | Cohort | Cauca-sian | Spain | 50 ± 13 | 139 (74.3) | 305 (71.9) | 611 | 187 (31) | 424 (69) | 3 (1.6) | 11 (2.5) | 64 (34.2) | 133 (31.4) | 34 (18.2) | 67 (15.8) | 4.9 ± 2.4 | 3.8 ± 2.3 | - | - | - | - |
| Seung Up Kim [51] | 2019 | Cohort | Asian | South Korea | 48.4 ± 11.7 | 889 (59.9) | 913 (64.6) | 2897 | 1484 (51.2) | 1413 (48.7) | 138 (9.2) | 102 (7.2) | 499 (33.6) | 411 (29.1) | 758 (51.1) | 694 (49.1) | 5.7 ± 2.1 | 5.4 ± 2.1 | 23.8 ± 4.5 | 23.8 ± 2.9 | 121 (8.15) | 106 (7.5) |
| Jonggi Choi [49] | 2019 | Cohort | Asian | Korea | 48.8 ± 10.5 | 965 (61.9) | 692 (60.6) | 2701 | 1560 (57.7) | 1141 (42.2) | 115 (7.3) | 39 (3.4) | 935 (59.9) | 653 (57.2) | 853 (54.7) | 641 (56.2) | 6.7 | 6.4 | - | - | 94 (6) | 62 (5.4) |
| Sung Won Lee [57] | 2020 | Cohort | Asian | South Korea | 47 | 926 (58.5) | 841 (58.4) | 3022 | 1583 (52.3) | 1439 (47.6) | 84 (5.3) | 50 (3.5) | 567 (35.82) | 483 (33.56) | 974 (61.5) | 823 (57.1) | 6.49 (5.28, 7.67) | 6.41 (5.34, 7.49) | 23.7 | 23.7 | 159 (10) | 105 (7.3) |
| Terry Cheuk-Fung Yip [60] | 2020 | Cohort | Asian | China | 52.9 ± 13.2 | 18,094 (47.3) | 591 (45.1) | 29,350 | 28,041 (95.5) | 1309 (4.5) | 1386 (4.9) | 8 (0.6) | 3822 (13.6) | 38 (2.9) | 8317 (29.7) | 721 (55.1) | 5.3 ± 2.2 | 4.9 ± 2.7 | - | - | 6366 (22.7) | 93 (7.1) |
| Ingyoon Ha [56] | 2020 | Cohort | Asian | South Korea | 45 | 558 (61) | 266 (63) | 1340 | 921 (68.7) | 419 (31.2) | 82 (8.9) | 24 (5.7) | 259 (28) | 39 (9.3) | 488 (53) | 261 (62) | 6.36 | 6.67 | 22.2 | 22.3 | 98 (11) | 22 (5) |
| George V. Papatheodoridis [55] | 2020 | Cohort | Cauca-sian | Europe | 52 ± 14 | 538 (70) | 827 (71) | 1951 | 772 (39.5) | 1163 (59.6) | 50 (6.5) | 93 (8) | 166 (21.5) | 358 (30.8) | 110 (14.2) | 233 (20) | - | - | 26.1 ± 3.8 | 25.8 ± 5.3 | 39 (7) | 77 (10.8) |
Abbreviations: entecavir (ETV); tenofovir (TDF); hepatocellular carcinoma (HCC); hepatitis B e antigen (HBeAg); body mass index (BMI); diabetes mellitus (DM).